Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Tempus AI Inc.

An announcement from Tongcheng Travel Holdings Limited ( ($HK:0780) ) is now available. Tongcheng Travel Holdings Limited reported a strong financi...

Tongcheng Travel Reports Strong Q3 2025 Financial Results

An announcement from SThree plc ( ($GB:STEM) ) is now available. SThree plc has announced transactions involving its senior management, specificall...

SThree plc Announces Management Share Transactions

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Tempus AI, Inc. Class A, with a price target of $88.00. Th...

TD Cowen Remains a Hold on Tempus AI, Inc. Class A (TEM)

Needham analyst Ryan MacDonald reiterated a Buy rating on Tempus AI, Inc. Class A today and set a price target of $100.00. The company’s shares clo...

Needham Sticks to Its Buy Rating for Tempus AI, Inc. Class A (TEM)

In a report released on October 31, Thomas Renaud from Kepler Capital maintained a Buy rating on Ateme SA, with a price target of €7.00. The compan...

Kepler Capital  Keeps Their Buy Rating on Ateme SA (0QVW)

The latest update is out from Stem Inc ( ($STEM) ). On October 29, 2025, Stem Inc issued a press release, which was furnished with Form 8-K. The in...

Stem Inc Issues Press Release with Form 8-K

In a report released today, Pavan Daswani from Citi maintained a Hold rating on Temenos. The company’s shares closed yesterday at $85.63. Daswani c...

Citi Sticks to Its Hold Rating for Temenos (TMNSF)

Canaccord Genuity analyst Kyle Mikson CFA maintained a Buy rating on Tempus AI, Inc. Class A today and set a price target of $91.02. The company’s ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TEM	$76.84	+1.03%	4.88M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TEM	$76.84	+1.0%	4.88M
3
4
5
6

TEM

TEM

Get Tempus AI Inc. Data in Excel

Get Tempus AI Inc. Data in Excel